IMPROVE-IT and genetics reaffirm the causal role of LDL in Cardiovascular Disease

Atherosclerosis

Volumn 241, Issue 2, 2015, Pages 498-501

  Catapano, Alberico L ^a   Ference, Brian A ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMBRANE PROTEIN; NPC1L1 PROTEIN, HUMAN;

ALLELE; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DNA POLYMORPHISM; DRUG EFFICACY; FOLLOW UP; GENETICS; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; UNSTABLE ANGINA PECTORIS; BLOOD; CARDIOVASCULAR DISEASES; DRUG APPROVAL; GENETIC PREDISPOSITION; MENDELIAN RANDOMIZATION ANALYSIS; METHODOLOGY;

CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DRUG APPROVAL; EZETIMIBE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEMBRANE PROTEINS; MENDELIAN RANDOMIZATION ANALYSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84931260952     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.06.008     Document Type: Note

References (16)

1. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278. Cholesterol Treatment Trialists' (CTT) Collaborators.
2. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681. Cholesterol Treatment Trialists' (CTT) Collaboration.
3. Morrone D., Weintraub W.S., Toth P.P., et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis 2012, 223:251-261.
4. Garcia-Calvo M., Lisnock J., Bull H.G., et al. The target of ezetimibe is Niemann-Pick C1-like 1 (NPC1L1). Proc. Natl. Acad. Sci. U. S. A. 2005, 102:8132-8137.
5. Kastelein J.J., Akdim F., Stroes E.S., et al. Enhance investigators: simvastatin with or without ezetimibe in familial hypercholesterolemia. N.Engl. J. Med. 2008, 358:1431-1443.
6. Taylor A.T., Villines T.C., Stanek E.J., et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N.Engl. J. Med. 2009, 361:2113-2122.
7. Willer C.J., Schmidt E.M., Sengupta S., et al. Discovery and refinement of loci associated with lipid levels. Nat. Genet. 2013, 45:1274-1283. Global Lipids Genetics Consortium.
8. Lawlor D.A., Harbord R.M., Sterne J.A., Timpson N. Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat. Med. 2008, 27:1133-1163.
9. Cohen J.C., Pertsemlidis A., Fahmi S., et al. Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:1810-1815.
10. Polisecki E.1, Peter I., Simon J.S., et al. Prospective study of pravastatin in the elderly at risk (PROSPER) investigators. Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly. J.Lipid Res. 2010, 51:1201-1207.
11. Deloukas P., Kanoni S., Willenborg C., et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat. Genet. 2013, 45:25-33. CARDIoGRAMplusC4D Consortium.
12. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N.Engl. J. Med. 2014, 371:2072-2082. Myocardial Infarction Genetics Consortium Investigators.
13. Ference B.A., Yoo W., Alesh I., et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J.Am. Coll. Cardiol. 2012, 60:2631-2639.
14. Ference B.A., Majeed F., Penumetcha R., Flack J.M., Brook R.D. Effect of naturally randomvallocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian randomization study. J.Am. Coll. Cardiol. 2015, 65:1552-1561.
15. Cannon Christopher P., Blazing Michael A., Giugliano Robert P., et al. For the IMPROVE-it Investigators June 3, 2015, 10.1056/NEJMoa1410489.
16. Swerdlow D.I., Preiss D., Kuchenbaecker K.B., et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2014, (14):61183-61191. S0140-6736.